SCHEMBL5409768

SCHEMBL5409768

COc1cccc(CCN(CCC(=O)O)C(=O)c2ccccc2-c2ccccc2C(=O)NCc2ccc(C)o2)c1OC

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 6/20 0.39
ALDH1A1 P00352 6/20 0.39
PKM P14618 4/20 0.39
KDM4E B2RXH2 3/20 0.39
MAPT P10636 2/20 0.39
HTT P42858 1/20 0.39
PDE10A Q9Y233 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
NPC1 O15118 1/20 0.37
TP53 P04637 2/20 0.37
TAS1R3 Q7RTX0 1/20 0.37
TAS1R1 Q7RTX1 1/20 0.37
GLA P06280 1/20 0.37
TSHR P16473 3/20 0.37
MAPK1 P28482 2/20 0.37
RCE1 Q9Y256 1/20 0.37
LMNA P02545 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5418600 0.88 HPGD (0.52) HPGDALDH1A1PKMKDM4EHTT
SCHEMBL5398275 0.88 TSHR (0.49) HPGDALDH1A1KDM4EMAPTTP53
SCHEMBL5406033 0.88 HPGD (0.45) HPGDALDH1A1KDM4EHTTPDE10A
SCHEMBL5394257 0.87 HPGD (0.51) HPGDALDH1A1KDM4EMAPTHTT
SCHEMBL5403505 0.86 HPGD (0.47) HPGDALDH1A1KDM4EMAPTTP53
SCHEMBL5405942 0.85 HPGD (0.46) HPGDALDH1A1KDM4EMAPTCYP1A2
SCHEMBL5418249 0.85 KMT2A (0.50) HPGDALDH1A1KDM4EMAPTHTT
SCHEMBL5406171 0.85 KCNA5 (0.45) HPGDALDH1A1KDM4EMAPTPDE10A
SCHEMBL5409762 0.85 MEN1 (0.37) HPGDPKMNPC1TSHRRAB9A
SCHEMBL5418495 0.85 RAB9A (0.46) HPGDALDH1A1KDM4ETP53TAS1R3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7285680-B2 β-alanine derivatives and the use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2007-10-23 US disclosed
US-20050256160-A1 Beta-alanine derivatives and the use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2005-11-17 US disclosed
EP-1533294-A1 BETA-ALANINE DERIVATIVE AND USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2005-05-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050256160-A1 Beta-alanine derivatives and the use thereof TGFB1, PML, APOB HPGD 1078/4885ALDH1A1 1256/4885PKM 880/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.